State Street’s Protara Therapeutics TARA Stock Holding History

State Street’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.24M	Buy	1,005,142 +434,264	+76%	+$2.57M	﹤0.01%	2938
2025 Q4	$3.04M	Buy	570,878 +220,787	+63%	+$1.23M	﹤0.01%	3199
2025 Q3	$1.52M	Buy	350,091 +59,184	+20%	+$192K	﹤0.01%	3421
2025 Q2	$881K	Buy	290,907 +207,707	+250%	+$716K	﹤0.01%	3512
2025 Q1	$354K	Buy	83,200 +1,000	+1%	+$4.47K	﹤0.01%	3683
2024 Q4	$434K	Buy	82,200 +55,600	+209%	+$180K	﹤0.01%	3653
2024 Q3	$48.7K	Hold	26,600	–	–	﹤0.01%	4108
2024 Q2	$55.3K	Hold	26,600	–	–	﹤0.01%	4125
2024 Q1	$107K	Sell	26,600 -4,300	-14%	-$13.9K	﹤0.01%	4021
2023 Q4	$57.8K	Hold	30,900	–	–	﹤0.01%	4172
2023 Q3	$51.6K	Hold	30,900	–	–	﹤0.01%	4281
2023 Q2	$73.9K	Hold	30,900	–	–	﹤0.01%	4303
2023 Q1	$95.8K	Hold	30,900	–	–	﹤0.01%	4338
2022 Q4	$82.8K	Hold	30,900	–	–	﹤0.01%	4427
2022 Q3	$91K	Hold	30,900	–	–	﹤0.01%	4495
2022 Q2	$91K	Hold	30,900	–	–	﹤0.01%	4565
2022 Q1	$158K	Buy	30,900 +1,100	+4%	+$5.78K	﹤0.01%	4471
2021 Q4	$201K	Buy	29,800 +7,000	+31%	+$48.3K	﹤0.01%	4351
2021 Q3	$158K	Buy	22,800 +12,441	+120%	+$97K	﹤0.01%	4431
2021 Q2	$101K	Sell	10,359 -49,774	-83%	-$564K	﹤0.01%	4365
2021 Q1	$946K	Buy	60,133 +10,100	+20%	+$187K	﹤0.01%	3632
2020 Q4	$1.21M	Buy	50,033 +27,015	+117%	+$582K	﹤0.01%	3526
2020 Q3	$387K	Buy	23,018 +4,861	+27%	+$113K	﹤0.01%	3599
2020 Q2	$532K	Buy	+18,157	New	+$562K	﹤0.01%	3535
2016 Q2	–	Sell	-2,361	Closed	-$729K	–	3762
2016 Q1	$729K	Buy	2,361 +874	+59%	+$282K	﹤0.01%	3285
2015 Q4	$924K	Buy	1,487 +123	+9%	+$72.2K	﹤0.01%	3223
2015 Q3	$758K	Buy	1,364 +183	+15%	+$113K	﹤0.01%	3260
2015 Q2	$844K	Buy	+1,181	New	+$731K	﹤0.01%	3280

Other funds holding TARA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

State Street's TARA Position: Q1 2026 in Review

State Street increased its Protara Therapeutics (TARA) stake by 76% in Q1 2026, buying an estimated $2.57M and bringing the position to 1,005,142 shares worth $5.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2938.

State Street first reported a position in TARA in Q2 2015 and has held it in 28 quarters since. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

State Street held 1,005,142 shares of Protara Therapeutics worth $5.24M as of Q1 2026.
State Street bought 434,264 Protara Therapeutics shares in Q1 2026, an estimated $2.57M.
Protara Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2938 holding.
State Street first reported a position in Protara Therapeutics in Q2 2015 and has held it in 28 quarters since.
114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.